Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells
Status:
Terminated
Trial end date:
2021-06-17
Target enrollment:
Participant gender:
Summary
Subjects will receive standard chemotherapy and Tumor Treated Fields (TTFields) and will also
receive Carvedilol for 4 cycles of treatment. Carvedilol will start at 6.25 mg orally twice a
day and be increased to 12.5 mg orally twice daily after 1 to 2 weeks if tolerated.
Peripheral glioma circulating tumor cells (CTC) and brain MRI with and without contrast will
be obtained at baseline, 2 cycles, and 4 cycles to determine the efficacy and direction of
change of the CTC using a new assay tool. Preliminary assessment of the tolerability of
Carvedilol with standard chemotherapy will also be evaluated.
Phase:
Early Phase 1
Details
Lead Sponsor:
West Virginia University
Collaborator:
West Virginia Clinical and Translational Science Institute